OCUL logo

Ocular Therapeutix Inc. (OCUL)

$10.64

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OCUL

Market cap

$2.34B

EPS

-1.4

P/E ratio

--

Price to sales

44.89

Dividend yield

--

Beta

0.967807

Price on OCUL

Previous close

$10.64

Today's open

$10.51

Day's range

$10.51 - $10.77

52 week range

$6.23 - $16.44

Profile about OCUL

CEO

Pravin U. Dugel

Employees

274

Headquarters

Bedford, MA

Exchange

NASDAQ Global Market

Shares outstanding

219615868

Issue type

Common Stock

OCUL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on OCUL

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.

news source

GlobeNewsWire • Sep 1, 2026

news preview

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

news source

Seeking Alpha • Aug 18, 2026

news preview

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).

news source

Benzinga • Aug 17, 2026

news preview

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Beth Rada, the Company's new SVP, Government Affairs and Public Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Aug 13, 2026

news preview

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI's annual dosing and clinic productivity benefits could drive adoption beyond wet AMD, targeting broader retinal indications including diabetic retinopathy. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, reducing near-term regulatory risk.

news source

Seeking Alpha • Aug 5, 2026

news preview

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026

news source

GlobeNewsWire • Aug 3, 2026

news preview

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.

news source

Zacks Investment Research • Aug 3, 2026

news preview

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on the planned filing package.

news source

MarketBeat • Jul 23, 2026

news preview

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

news source

GlobeNewsWire • Jul 1, 2026

news preview

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data

news source

GlobeNewsWire • Jun 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ocular Therapeutix Inc.

Open an M1 investment account to buy and sell Ocular Therapeutix Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OCUL on M1